The Conversation (0)
Medtronic Launches ENCHANT Study to Evaluate ChEVAR Parallel Graft Technique with the Endurant(TM) II/IIs Stent Graft System
Jan. 24, 2018 09:13AM PST
Medical Device Investing
Medtronic (NYSE: MDT) announced the launch of the ENCHANT study. The post-market, non-interventional, multi-center, non-randomized, single-arm study will enroll approximately 150 patients across 25 sites in Europe and Russia, and will evaluate the safety and performance of a ChEVAR procedure using the Endurant(TM) II/IIs stent graft system in a real-world setting. As quoted in the …
Medtronic (NYSE: MDT) announced the launch of the ENCHANT study. The post-market, non-interventional, multi-center, non-randomized, single-arm study will enroll approximately 150 patients across 25 sites in Europe and Russia, and will evaluate the safety and performance of a ChEVAR procedure using the Endurant(TM) II/IIs stent graft system in a real-world setting.
As quoted in the press release:
“We are excited to initiate this study in a real-world population, which will build upon existing clinical evidence for the ChEVAR technique as a standardized approach for treating short infrarenal necks,” said Prof. Torsello, M.D. “We believe the study marks another significant milestone for patients with complex forms of aortic disease who, until recently, had not been suitable for a minimally-invasive endovascular procedure.”
